Aptalis Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aptalis Pharma Inc.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.
The WHO calls the "COVID Zero" containment policy that Beijing is doubling down on "unsustainable," while a new study has shed light on the potential cost of moving away from cutting transmissions to mitigating disease.
It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.
- Other Names / Subsidiaries
- Axcan Pharma, Inc.
- Eurand N.V.
- Mpex Pharmaceuticals, Inc.